For the quarter ending 2025-09-30, TNYA made $21,598K in revenue. -$20,274K in net income. Net profit margin of -93.87%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 15,363 | 17,370 | ||
| General and administrative | 5,573 | 6,712 | ||
| Total operating expenses | 20,936 | 24,082 | ||
| Loss from operations | -20,936 | -24,082 | ||
| Interest income | 658 | 815 | ||
| Other income (loss), net | 3 | -16 | ||
| Total other income, net | 661 | 799 | ||
| Net loss before income tax expense | -20,275 | -23,283 | ||
| Net loss | -20,275 | -23,283 | ||
| Net unrealized gain (loss) on marketable securities | 1 | 9 | ||
| Comprehensive loss | -20,274 | -23,274 | ||
| Earnings per share, diluted, total | -0.12 | -0.14 | ||
| Net loss per share, basic | -0.12 | -0.14 | ||
| Weighted-average shares used in computing net loss per share, basic | 163,345,972 | 162,791,579 | ||
| Weighted-average shares used in computing net loss per share, diluted | 163,345,972 | 162,791,579 | ||
Tenaya Therapeutics, Inc. (TNYA)
Tenaya Therapeutics, Inc. (TNYA)